A5028626044- Estrogen and related hormone effects
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Cancer Risks and Factors
- Childhood Cancer Survivors' Quality of Life
- Cannabis and Cannabinoid Research
- Mechanical Circulatory Support Devices
- Cancer Diagnosis and Treatment
- Medical Device Sterilization and Disinfection
- Safe Handling of Antineoplastic Drugs
- Bone and Joint Diseases
- Cancer Treatment and Pharmacology
- Male Breast Health Studies
- Chemotherapy-induced cardiotoxicity and mitigation
- Cardiac Arrest and Resuscitation
- Pluripotent Stem Cells Research
- Perfectionism, Procrastination, Anxiety Studies
- HER2/EGFR in Cancer Research
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Child and Adolescent Psychosocial and Emotional Development
- BRCA gene mutations in cancer
- CRISPR and Genetic Engineering
- Pharmaceutical Practices and Patient Outcomes
- Healthcare Systems and Technology
- Bone health and treatments
Breast Cancer Alliance
2018-2024
Utah Valley Regional Medical Center
2019
Dana-Farber Cancer Institute
2010-2018
Swedish Medical Center
2017
American Society of Clinical Oncology
2010-2016
UPMC Hillman Cancer Center
2010-2016
The University of Texas MD Anderson Cancer Center
2014-2016
Memorial Sloan Kettering Cancer Center
2010-2014
Roswell Park Comprehensive Cancer Center
2012
University of Rochester Medical Center
2012
To update the ASCO clinical practice guideline on adjuvant endocrine therapy basis of emerging data optimal duration treatment, particularly tamoxifen.ASCO convened Update Committee and conducted a systematic review randomized trials from January 2009 to June 2013 analyzed three historical trials. Guideline recommendations were based Committee's evidence. Outcomes interest included survival, disease recurrence, adverse events.This reflects tamoxifen treatment. There have been five studies...
Purpose To update the ASCO clinical practice guideline on adjuvant endocrine therapy based emerging data about optimal duration of aromatase inhibitor (AI) treatment. Methods conducted a systematic review randomized trials from 2012 to 2018. Guideline recommendations were Panel’s evidence six trials. Results The included studies AI treatment beyond 5 years demonstrated that extension was not associated with an overall survival advantage but significantly lower risks breast cancer recurrence...